DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Merimepodib
Merimepodib
N° 17196
COVID-19 Drugs: Are There Any That Work? 24 August 2020, by from Mayo Clinic News Network, Mayo Clinic News Network
COVID-19: Predicting Inhibition of the Main Protease and Therapeutic Intracellular Accumulation and Plasma and Lung Concentratio
Antivirals Against the Chikungunya Virus
What's in the Pipeline: New HIV Drugs, Vaccines, Microbicides, HCV And
Differences in Clinical Outcomes Among Hepatitis C Genotype 1
Existing Drugs Considered As Promising in COVID-19 Therapy
Anti-Tumor Potential of IMP Dehydrogenase Inhibitors: a Century-Long Story
24 March 2011 (24.03.2011) W O 201 1 /03 523 1 a 1
(12) Patent Application Publication (10) Pub. No.: US 2008/0161324 A1 Johansen Et Al
A SARS-Cov-2 Protein Interaction Map Reveals Targets for Drug Repurposing
Technology Report No 47
The IMPDH Inhibitor Merimepodib Suppresses SARS-Cov-2 Replication in Vitro
Current Role in the Optimal Clinical Management of Chronic Hepatitis Cq
(VX-497) and Interferon-Α in Previously
Prevalence Clotting Factor Treatment Prior to 1987 Blood Long-Term Transfusion Worldwide 170 Million ( 3%) Hemodialysis Or Organ Transplant Prior to 1992
Hepatitis C Virus
Antivirals Against the Chikungunya Virus
Top View
COVID-19 Issues Issue 3
(12) Patent Application Publication (10) Pub. No.: US 2015/0150897 A1 Denning Et Al
Evolving Drug Therapies for Chronic Hepatitis C Immunomodulation and Beyond
Vertex Pharmaceuticals Receives Distinguished Recognition by Scientific American Magazine
The IMPDH Inhibitor Merimepodib Provided in Combination with The
Screening Tools for the Identification of Alphavirus Inhibitors
WHO HIV 2014.26 Eng.Pdf
And PEGINTERFERON ALFA-2
The Present and Emerging Investigational Drugs for Chronic Hepatitis C: Current Status R Kumar
Drug Repurposing in the Treatment of COVID-19 COVİD-19 Tedavisinde İlaç Yeniden Konumlandırma
Embase 1988 to 2014 Week 36, Ovid MEDLINE(R) In-Process
Vertex Pharmaceuticals Reports Data Suggesting Potential for Oral Combination Approaches in Treatment of HCV
Downloaded Pro- Tein Containing the Full-Length Structure
NIH Public Access Author Manuscript Hepatology
Covid-19 Vaccine Safety Briefing Report
(12) United States Patent (10) Patent No.: US 9,642,865 B2 Liu Et Al
Download Product Insert (PDF)
Vaccines and Therapies in Development for SARS-Cov-2 Infections
Potential Anti-SARS-Cov-2 Therapeutics That Target the Post-Entry Stages of the Viral Life Cycle: a Comprehensive Review
New Treatment Strategies Against Hepatitis C Viral Infection
Remdesivir from Wikipedia, the Free Encyclopedia
In Silico Repositioning for Dual Inhibitor Discovery of SARS-Cov-2 (COVID- 19) 3C-Like Protease and Papain-Like Peptidase
The Antiparasitic Drug Atovaquone Inhibits Arbovirus Replication Through the Depletion Of
Virtual Screen for Repurposing of Drugs for Candidate Influenza a M2
Prioritisation of Potential Anti-SARS-Cov-2 Drug Repurposing
X. the Future of HCV Therapy: Viral Targets and Drug Development
Merimepodib a Host Directed Antiviral for the Treatment of COVID-19
(12) United States Patent (10) Patent No.: US 8,980,930 B2 Liu Et Al
Towards Antivirals Against VHF Viruses
Supplemental Table 1: Inclusion and Exclusion Criteria
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri